Abstract: The present invention relates to substituted benzofused derivatives, which can he used as vanilloid receptor ligands, method of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.
Abstract: The present invention relates to novel pyrazolyl-substituted heterocycles of the formula (I) in which X, Y, Z and Het are as defined in the disclosure, to processes for their preparation, and to their use as pesticides, microbicides and herbicides.
Type:
Application
Filed:
November 12, 2009
Publication date:
March 11, 2010
Inventors:
Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Axel Trautwein, Ralf Wischnat, Christoph Erdelen, Angelika Lubos-Erdelen, Dieter Feucht, Mark Wilhelm Drewes
Abstract: The present invention is directed to compounds of Formula I: I (where A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Abstract: The present invention relates to novel pyrazolyl-substituted heterocycles of the formula (I) in which X, Y, Z and Het are as defined in the disclosure, to processes for their preparation, and to their use as pesticides, microbicides and herbicides.
Type:
Grant
Filed:
July 21, 2008
Date of Patent:
January 5, 2010
Assignee:
Bayer CropScience AG
Inventors:
Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Axel Trautwein, Ralf Wischnat, Christoph Erdelen, Angelika Lubos-Erdelen, legal representative, Dieter Feucht, Mark Wilhelm Drewes
Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
Type:
Application
Filed:
May 8, 2008
Publication date:
February 12, 2009
Inventors:
Varghese John, Michel Maillard, Barbara Jagodzinska, Jose Aquino, Gary Probst, Jay Tung
Abstract: The present invention provides a compound of Formula (I): wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C7-C14 aralkyl group and —C(?O)Rx; Rx represents an optionally substituted C1-C6 alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted C1-C6 alkoxy group or —NReRf; Ar1 represents an optionally substituted aromatic carbocyclic ring or an optionally mono-substituted aromatic heterocyclic ring; Q represents —(CH2)m-(L)p- or -(L)p-(CH2)m—; m represents an integer selected from 0 to 2, n represents an integer selected from 1 and 2, and p represents an integer selected from 0 and 1; L represents —O—, —S— or —NR5—; and A represents an optionally substituted aryl group or an optionally substituted heteroaryl group, a prodrug thereof and a pharmaceutically acceptable salt thereof, as well as a pharmaceutical preparation or pharmaceutical co
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
Type:
Application
Filed:
July 9, 2008
Publication date:
January 22, 2009
Inventors:
Yat Sun Or, Lu Ying, Ce Wang, Yao-Ling Qiu
Abstract: The present invention relates to novel pyrazolyl-substituted heterocycles of the formula (I) in which X, Y, Z and Het are as defined in the disclosure, to processes for their preparation, and to their use as pesticides, microbicides and herbicides.
Type:
Application
Filed:
July 21, 2008
Publication date:
November 27, 2008
Inventors:
Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Axel Trautwein, Ralf Wischnat, Christoph Erdelen, Angelika Lubos-Erdelen, Dieter Feucht, Mark Wilhelm Drewes
Abstract: The present invention relates to novel pyrazolyl-substituted heterocycles of the formula (I) in which X, Y, Z and Het are as defined in the disclosure, to processes for their preparation, and to their use as pesticides, microbicides and herbicides.
Type:
Grant
Filed:
April 17, 2007
Date of Patent:
October 14, 2008
Assignee:
Bayer CropScience AG
Inventors:
Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Axel Trautwein, Ralf Wischnat, Angelika Lubos-Erdelen, legal representative, Dieter Feucht, Mark Wilhelm Drewes, Christoph Erdelen
Abstract: The subject of the invention is tricyclic derivatives of pyrazolecarboxylic acid of formula: in which R1 represents a C3-C15 carboxyl radical or an NR2R3 group. The invention also relates to the method for preparing the compounds of formula (I), pharmaceutical compositions containing them. The compounds of formula (I) are active on cannabinoid CB1 receptors.
Type:
Grant
Filed:
April 29, 2005
Date of Patent:
June 10, 2008
Assignee:
Sanofi-Aventis
Inventors:
Francis Barth, Christian Congy, Serge Martinez, Murielle Rinaldi
Abstract: An intramolecular [3+2] cycloaddition reaction of a hydrazone is carried out under a mild condition with a high stereoselectivity and yield by reacting a hydrazone derivative in the presence of an asymmetric catalyst system obtained by mixing a zirconium alkoxide represented by the following formula (I): Zr(OR)4 ??(I) (wherein R is a hydrocarbon group which may have a substituent) with a binaphthol derivative represented by the following formula (II): (wherein Y1 and Y2 are each identical or different and denote a hydrogen atom or a halogen atom, and at least one of Y1 and Y2 denotes a halogen atom).
Type:
Grant
Filed:
March 11, 2003
Date of Patent:
April 1, 2008
Assignee:
Japan Science and Technology Agency
Inventors:
Shu Kobayashi, Yasuhiro Yamashita, Haruro Ishitani
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Abstract: The present invention relates to novel pyrazolyl-substituted heterocycles of the formula (I) in which X, Y, Z and Het are as defined in the disclosure, to processes for their preparation, and to their use as pesticides, microbicides and herbicides.
Type:
Grant
Filed:
October 21, 2002
Date of Patent:
June 12, 2007
Assignee:
Bayer CropScience, AG
Inventors:
Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Axel Trautwein, Ralf Wischnat, Angelika Lubos-Erdelen, legal representative, Dieter Feucht, Mark Wilhelm Drewes, Christoph Erdelen, deceased
Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein
Abstract: The present invention relates to novel compounds of the formula (I) 1
Type:
Application
Filed:
May 21, 2004
Publication date:
November 4, 2004
Inventors:
Reiner Fischer, Thomas Bretschneider, Axel Trautwein, Astrid Ullmann, Mark Wilhelm Drewes, Christoph Erdelen, Peter Dahmen, Dieter Feucht, Rolf Pontzen
Abstract: There are provided methods for the treatment of diseases involving dysfunction of the peripheral and central nervous system comprising administering one or more Spiro compounds. Also provided and pharmaceutical compositions useful in such methods, compounds for use in the preparation of such pharmaceutical compositions, processes for preparing compounds useful in the practice of such methods, and some novel such compounds per se.
Type:
Application
Filed:
May 2, 2003
Publication date:
March 4, 2004
Applicant:
ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH
Inventors:
Abraham Fisher, Nira Bar-Ner, Yishai Karton
Abstract: Photochromic pyran compounds and their use in synthetic resin objects of all types, especially for ophthalmic applications, particularly spiro compounds having a fluorene structure derived from naphthopyrans, which are known as spirofluorenopyrans. By introducing respectively only one strongly electron donating or withdrawing group at specific positions in the periphery of the pyran dye, photochromic compounds obtained which in the excited state are distinguished by an expanded color spectrum, while simulataneously offering comparably good bleaching rates and good durability.
Abstract: The present invention relates to a photochromic spirobenzopyran compound of the formula (1) and its derivatives, a spirobenzopyran group having unsaturated terminal groups, a polymer prepared therefrom, a method for the production thereof, a composition comprising said spirobenzopyran or said spirobenzopyran group-containing polymer and a photochromic switch film using the same: 1
Type:
Application
Filed:
August 24, 1999
Publication date:
May 29, 2003
Inventors:
EUN-KYOUNG KIM, YUN-KI CHOI, SAM-ROK KEUM
Abstract: Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
Type:
Application
Filed:
December 5, 2001
Publication date:
December 19, 2002
Inventors:
Jayasree Vasudevan, Alan T. Johnson, Dehua Huang, Roshantha A. Chandraratna
Abstract: This invention relates to substituted indoline derivative compounds which are antagonists of the progesterone receptor, their preparation and pharmaceutical utility, particularly including contraception and treatment of benign or malignant neoplastic diseases, having the general structure: 1
Type:
Application
Filed:
December 14, 2001
Publication date:
July 4, 2002
Applicant:
American Home Products Corporation
Inventors:
Andrew Fensome, Lori L. Miller, John W. Ullrich, Reinhold H. W. Bender, Puwen Zhang, Jay E. Wrobel, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
Abstract: Compounds of the general structural formula I
are selective NPY Y5 receptor antagonists. The compounds and compositions of the present invention are useful in the treatment of obesity and complications associated therewith.
Type:
Grant
Filed:
November 8, 1999
Date of Patent:
February 20, 2001
Assignees:
Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
Inventors:
Ying-Duo Gao, Douglas J. MacNeil, Lihu Yang, Nancy R. Morin, Takehiro Fukami, Akio Kanatani, Takahiro Fukuroda, Yasuyuki Ishii, Masaki Ihara